1 alpha-hydroxyvitamin D3 treatment of therapy-resistant symptomatic hypocalcemia in a hypoparathyroid patient with intestinal malabsorption.
The case history of a hypoparathyroid female with short bowel syndrome and long-standing therapy-resistant symptomatic hypocalcemia is reported. During treatment with massive doses of the potent vitamin D analog, 1 alpha-hydroxyvitamin D3(1 alpha(OH)D3), normocalcemia was re-established and clinical symptoms of hypocalcemia were relieved. Furthermore, significant improvement of t of intestinal calcium absorption and bone mineral content was observed after three months of treatment with 1 alpha(OH)D3. The data suggest that 1 alpha(OH)D3 may be of therapeutical value in patients with hypoparathyroidism and intestinal malabsorption.
D000368:Aged; D002118:Calcium / Q000378:metabolism; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D006996:Hypocalcemia / Q000188:drug therapy* / Q000209:etiology; D007011:Hypoparathyroidism / Q000150:complications* / Q000188:drug therapy; D007408:Intestinal Absorption; D008286:Malabsorption Syndromes / Q000150:complications* / Q000188:drug therapy*
D006887:Hydroxycholecalciferols; D002118:Calcium